XTNTXTNTHealthcare · Medical Devices

XTNT Stock Forecast: Xtant Medical Holdings, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.21
−4.55% on the day

The median 12-month analyst price target for Xtant Medical Holdings, Inc. is $0.75. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 51 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$29.5M
Ticker Nerd rank
51/ 100
Median analyst target
$0.75
Analysts covering
3
Revenue$23.0M−35.0% y/y
Operating income−$4.2M
Net income−$9.4M
Free cash flow−$7.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.2%
1M
−30.0%
YTD
−73.1%
1Y
−67.7%
From 52W high
−74.1%
From 52W low
0.0%
$0.21
$0.81
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Xtant Medical Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
51/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
93
Issuance
87
Quality
58
Value
47
Volatility
44
Momentum
34
Revisions
21
Growth
14

Accruals (93): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (14): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XTNT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XTNT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.20$0.40$0.60$0.80$1.00Jan 26Apr 26Jul 26Oct 26XTNTHigh $1.00Median $0.75Low $0.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2
Buy
1
Hold
0
Sell
$0.50
Low
$0.75
Median
$1.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Sept 2026LUCID CAPITAL MARKETSInitiatesBuy—
13 May 2026BTIGReiteratesBuy—
31 Mar 2026BTIGMaintainsBuy—
11 Nov 2025BTIGMaintainsBuy—
16 May 2024BTIGMaintainsBuy—
5 Dec 2023BTIGInitiatesBuy—
11 July 2023Craig-HallumMaintainsBuy—
26 Apr 2023Craig-HallumInitiatesBuy—
17 May 2019Maxim GroupDowngradeHold—
8 Dec 2016Maxim GroupInitiatesBuy—
30 Nov 2016Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for XTNT.

Market Radar

This page is one stock. Monday covers all of them.

XTNT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XTNT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Xtant Medical Holdings, Inc. returned −67.7% against +6.9% for the S&P 500, dividends included.

XTNT vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26XTNTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XTNT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.3×

Cheaper than 86% of US stocks

Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
57.9%

Higher than 71% of US stocks

Operating margin
−11.0%

Higher than 26% of US stocks

Net margin
—
Returns & dividend
Return on equity
−36.5%

Higher than 25% of US stocks

Return on assets
−7.6%

Higher than 29% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xtant Medical Holdings, Inc. has a market value of $29.5M and an enterprise value of $46.6M.

  • Revenue in the twelve months to 30 June 2026: $109.5M. The latest quarter shrank 35.0% year on year.

  • Net income over the same four quarters: −$11.1M, a −10.2% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.08.

  • Free cash flow in the twelve months to 30 June 2026: −$696K.

  • Shares outstanding: 140.3M.

  • Xtant Medical Holdings, Inc. employs 151 people — $725K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

XTNT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
XTNTXtant Medical Holdings, Inc.$29.5M51
NSYSNortech Systems, Inc.$29.4M82
NSPRInspireMD, Inc.$29.2M73
QTIQT Imaging Holdings, Inc.$28.1M20
TELATELA Bio, Inc.$31.1M36
MYOMyomo, Inc.$32.1M62
MDAISpectral AI, Inc.$33.5M26

Take a look at XTNT’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Xtant Medical Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about XTNT

What is the XTNT stock price forecast for 2026-2027?

The median 12-month analyst price target for Xtant Medical Holdings, Inc. is $0.75, with estimates ranging from $0.5 to $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XTNT stock a buy right now?

Of the 3 analysts covering Xtant Medical Holdings, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xtant Medical Holdings, Inc. 51 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XTNT?

As at 21 Nov 2026, Xtant Medical Holdings, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (93 of 100).

Will XTNT stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $0.75, and Ticker Nerd's factor model ranks Xtant Medical Holdings, Inc. 51 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XTNT stock forecast for 2030?

No analyst covering Xtant Medical Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XTNT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.5 to $1 over the next 12 months.

How has XTNT stock performed over the past year?

Xtant Medical Holdings, Inc. returned -67.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xtant Medical Holdings, Inc. do?

Xtant Medical Holdings, Inc. is a medical technology company that develops, manufactures, and markets regenerative medicine products and spinal implant systems for orthopedic and neurological surgeons. Its product portfolio includes orthobiologics, bone graft substitutes, biologic scaffolds, tissue-based products, and spinal fixation devices used in procedures involving spinal fusion, bone healing, and the treatment of complex spine and orthopedic conditions.

Company

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. is a medical technology company that develops, manufactures, and markets regenerative medicine products and spinal implant systems for orthopedic and neurological surgeons. Its product portfolio includes orthobiologics, bone graft substitutes, biologic scaffolds, tissue-based products, and spinal fixation devices used in procedures involving spinal fusion, bone healing, and the treatment of complex spine and orthopedic conditions. The company also serves related surgical areas such as chronic wound care, sports medicine, cranial repair, and foot and ankle applications. Xtant Medical Holdings, Inc. focuses on products that support surgical reconstruction and biologic healing across domestic and international markets. Based in Belgrade, Montana, the company operates as a specialized supplier within the medical device and regenerative medicine sectors.

CEO Mr. Sean E. Browne · 151 employees · United States · https://xtantmedical.com